Paolo Rivela

Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.

R. Foà, M. Boccadoro, G. Gaidano, 2021, Blood.

Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis

M. Marchetti, Claudia Bertassello, Manuela Canicattì, 2022, Journal of clinical medicine.

MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL.

R. Moia, A. Ferrario, M. Deodato, 2022, Blood.

SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia

B. Falini, F. Passamonti, A. Romano, 2022, British journal of haematology.

Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice

D. Pietrasanta, M. Zanni, G. Catania, 2023, Cancers.

The black swan: a case of central nervous system graft-versus-host disease

R. Tavarozzi, Paolo Rivela, Francesco Zallio, 2023, Journal of basic and clinical physiology and pharmacology.